Dr. Subhankar Chakraborty, MD

Dr. Chakraborty practices at OSU Internal Medicine in Westerville, Ohio.

Dr. Chakraborty's NPI, 1851685812, was assigned on June 7, 2011. Dr. Chakraborty holds Ohio license 35138274.

Dr. Chakraborty's primary practice is OSU Internal Medicine, at 6100 N Hamilton Rd, Westerville, OH 43081 in Franklin County. The practice phone is (614) 293-2229.

Dr. Chakraborty's primary practice is OSU Internal Medicine in Westerville, Ohio. Dr. Chakraborty is also affiliated with Ohio State University Hospital. The medical group on file is Ohio State University Physicians. Dmand AI also links Dr. Chakraborty to 1 more hospital and 10 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chakraborty practices, 2 sites in all. Vendor and product names are available with a free account.

Gastroenterology is Dr. Chakraborty's primary specialty in the NPI Registry, under taxonomy code 207RG0100X. Dmand AI has Dr. Chakraborty's licenses on file in 3 states: Ohio, Minnesota and Nebraska.

CMS data shows 375 Medicare services from Dr. Chakraborty across 11 procedure codes in 2024, for 282 Medicare patients. Medicare paid $31,438 for them.

CMS counts 282 Medicare patients who saw Dr. Chakraborty in 2024. The largest group is 65 to 74, with 131 patients. 74% of them have high blood pressure, and 71% have high cholesterol. 16% are also on Medicaid. Their average risk score is 1.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Chakraborty's median patient age at 54, with 64% women.

In 2024, Dr. Chakraborty wrote 1,141 Medicare Part D claims for 171 patients. 82% of them were for generic drugs. CMS names the drug for 959 of them, across 26 drugs with 11 or more claims each, at $402,817 in total drug cost. In 2023, CMS named 1,127 claims across 29 drugs.

Dr. Chakraborty accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chakraborty as offering telehealth. CMS counts 70 procedures of upper gastrointestinal (gi) endoscopy for acid reflux by Dr. Chakraborty, more than 69% of the clinicians it reports for that procedure.

Dmand AI links 61 papers to Dr. Chakraborty, published from 2010 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Pancreatic Neoplasms, Cell Line, Tumor and Mucin-4. Dr. Chakraborty has published most often in Neurogastroenterol Motil. Dr. Chakraborty's most frequent co-authors are Surinder K. Batra, MD, Michael J. Baine, MD and Aaron R. Sasson, MD.

Dmand AI links Dr. Chakraborty to 1 clinical trial. Conditions studied include Fecal Incontinence and Diarrhea.

CMS Open Payments shows 9 general payments to Dr. Chakraborty from 8 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 75% of the total. Sanofi and Genzyme US Companies paid the most, $4,892.